Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)

• ClinicalTrials.gov Identifier: NCT02717455
• Recruitment Status: Active, not recruiting
• First Posted: March 23, 2016
• Last Update Posted: April 11, 2022
• Sponsor: Pediatric Brain Tumor Consortium
• Information provided by (Responsible Party): Pediatric Brain Tumor Consortium

Tracking Information

• First Submitted Date: February 22, 2016
• First Posted Date: March 23, 2016
• Last Update Posted Date: April 11, 2022
• Actual Study Start Date: June 28, 2016
• Actual Primary Completion Date: February 14, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 21, 2017)

• To describe the toxicity profile and the dose-limiting toxicities of panobinostat in children with recurrent/progressive DIPG [ Time Frame: 26 courses (approximately 2 years) ]
  Adverse Events
• To estimate the maximum-tolerated dose and/or the recommended-phase 2 dose of panobinostat in children with recurrent/progressive DIPG [ Time Frame: Course 1 (the first 4 weeks of treatment) ]
  Dose Finding
• To evaluate and characterize the plasma pharmacokinetics of panobinostat in children with recurrent/progressive DIPG [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics
• To describe the toxicity profile and define the dose-limiting toxicities of panobinostat in children with non-progressed DIPG treated with 3 times/week, every other week. [ Time Frame: 26 courses (approximately 2 years) ]
  Adverse Events
• To estimate the maximum-tolerated dose and/or the recommended-phase 2 dose of panobinostat administered 3 times/week, every other week in children with non-progressed DIPG [ Time Frame: Course 1 (the first 4 weeks of treatment) ]
  Dose Finding
• To evaluate and characterize the plasma pharmacokinetics of panobinostat administered 3 times/week, every other week in children with non-progressed DIPG [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics

Original Primary Outcome Measures (submitted: March 17, 2016)

• To describe the toxicity profile and the dose-limiting toxicities of panobinostat in children with recurrent/progressive DIPG [ Time Frame: 26 courses (approximately 2 years) ]
  Adverse Events
• To estimate the maximum-tolerated dose and/or the recommended-phase 2 dose of panobinostat in children with recurrent/progressive DIPG [ Time Frame: Course 1 (the first 4 weeks of treatment) ]
  Dose Finding
• To evaluate pharmacokinetic parameters of apparent volume of the central compartment (Vc/F) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics
• To evaluate pharmacokinetic parameters of elimination rate constant (Ke) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics
• To estimate pharmacokinetic parameters of half-life (t1/2) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics
• To estimate pharmacokinetic parameters of apparent oral clearance (CL/F) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics
• To estimate pharmacokinetic parameters of area under the plasma concentration time curve (AUC) [ Time Frame: Course 1, Day 1 and Day 3 sample collections ]
  Plasma Pharmacokinetics

Current Secondary Outcome Measures (submitted: September 21, 2017)

• To describe the progression-free survival (PFS) and overall survival (OS) of children with recurrent or progressive DIPG who are treated with panobinostat [ Time Frame: 26 courses (approximately 2 years) ]
  Evaluated Response per imaging or clinical progression
• To describe the progression-free survival (PFS) and overall survival (OS) of children with non-progressed DIPG who are treated with panobinostat [ Time Frame: 26 courses (approximately 2 years) ]
  Evaluated Response per imaging or clinical progression
• To identify histone 3 K27M mutations in peripheral blood and urine, and evaluate changes with treatment. [ Time Frame: Day 1 of courses 1, 2, 4, 6, and 12 ]
  Pharmacodynamics: Cell-free DNA - Blood and Urine (Optional)

Original Secondary Outcome Measures (submitted: March 17, 2016)

• To describe the progression-free survival (PFS) and overall survival (OS) of children with recurrent or progressive DIPG who are treated with panobinostat [ Time Frame: 26 courses (approximately 2 years) ]
  Evaluated Response per imaging or clinical progression
• To identify histone 3 K27M mutations in peripheral blood and urine, and evaluate changes with treatment. [ Time Frame: Day 1 of courses 1, 2, 4, 6, and 12 ]
  Pharmacodynamics: Cell-free DNA - Blood and Urine (Optional)

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
• Official Title: Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Brief Summary

This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG that has not yet gotten worse.

Currently, only Stratum 2 is enrolling patients.

Detailed Description

Description

This is a multicenter, phase 1 trial of Panobinostat (LBH589) for children with diffuse intrinsic pontine glioma tumors.

Panobinostat is a pan-HDAC inhibitor of Class I, II and IV histone deacetylases (HDACs) involved in the deacetylation of histone and non-histone cellular proteins. Panobinostat inhibits purified total cellular histone deacetylase activity (IC50 = 0.03 uM) and activities of most HDAC isoforms (IC50 <10nM). In addition, panobinostat induces expression of the cell-cycle control genes including CDKN1A (p21), and selectively inhibits the proliferation of a variety of tumor cells compared to normal cells. It has been extensively profiled for its in vitro and in vivo pharmacological activity on a variety of tumor cell lines and tumor xenograft mice models.

Based on the in vitro and in vivo activity of panobinostat in preclinical models using DIPG cell cultures and orthotopic xenograft model systems, and the potentially important role of histone deacetylases and histone 3 K27M mutations in relation to pontine malignancies, the investigators are conducting a Phase 1 study of panobinostat in children with recurrent/progressive DIPG.

The primary objectives of the study are to (1) describe the toxicity profile and define the dose-limiting toxicities of panobinostat in children with recurrent/progressive DIPG, or with non-progressed DIPG taken every other week; (2) estimate the maximum tolerated dose and/or the recommended Phase 2 dose of panobinostat in children with recurrent/progressive DIPG, or with non-progressed DIPG taken every other week; and (3) evaluate and characterize the plasma pharmacokinetics of panobinostat in children with recurrent/progressive DIPG, or with non-progressed DIPG taken every other week.

Schema

STRATUM 1:

Only patients with recurrent or progressive DIPG will be enrolled initially. Panobinostat will be administered every other day, 3 times/week, p.o. preferably on a Monday/Wednesday/Friday schedule for three weeks, followed by a rest period. Three weeks of therapy plus the one week rest period (total 4 weeks) will constitute one course. Treatment will continue for up to two years (26 courses) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-study criteria.

The starting dose (dose level 1) is 10 mg/m2/day. Below are the proposed dose levels to be studied:

Dose level # Panobinostat oral dose (mg) Minimum BSA Restriction

0*: 5 mg/m2/day MWF, three weeks on, one week off (1 course = 28 days). Patients must have a BSA ≥ 0.80 m2.

1 (starting dose level): 10 mg/m2/day MWF, three weeks on, one week off, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

2: 16 mg/m2/day MWF, three weeks on, one week off, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

3: 22 mg/m2/day MWF, three weeks on, one week off, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

4: 28 mg/m2/day MWF, three weeks on, one week off, (1 course = 28 days). Patients must have a BSA ≥ 0.50 m2.

5: 36 mg/m2/day MWF, three weeks on, one week off, (1 course = 28 days). Patients must have a BSA ≥ 0.50 m2.

Panobinostat will be administered as a single agent

* Dose level 0 represents a potential treatment dose for patients requiring a dose reduction from dose level 1 and may be used as a contingency dose level if the starting dose level of panobinostat is not tolerated in the initial cohort.

STRATUM 2:

Patients with DIPG who have received adequate radiation therapy but have not yet progressed will be enrolled in the currently open Stratum 2. Panobinostat will be administered every other day, 3 times/week, every other week p.o. preferably on a Monday/Wednesday/Friday schedule. Total 4 weeks will constitute one course. Treatment will continue for up to two years (26 courses) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.

The starting dose (dose level 1) is 16 mg/m2/day. Below are the proposed dose levels to be studied:

Dose level # Panobinostat oral dose (mg) Minimum BSA Restriction

Negative 1*: 5 mg/m2/day MWF, every other week (1 course = 28 days). Patients must have a BSA ≥ 0.80 m2.

0*: 10 mg/m2/day MWF, every other week, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

1 (expected starting dose level): 16 mg/m2/day MWF, every other week, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

2: 22 mg/m2/day MWF, every other week, (1 course = 28 days). Patients must have a BSA ≥ 0.65 m2.

3: 28 mg/m2/day MWF, every other week, (1 course = 28 days). Patients must have a BSA ≥ 0.50 m2.

4: 36 mg/m2/day MWF, every other week, (1 course = 28 days). Patients must have a BSA ≥ 0.50 m2.

Panobinostat will be administered as a single agent

* Dose levels 0 and -1 represent potential treatment doses for patients requiring a dose reduction from dose level 1 and may be used as a contingency dose level if the starting dose level of panobinostat is not tolerated in the initial cohort.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Glioma

Intervention

Drug: LBH589

STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.

STRATUM 2: Non-progressed DIPG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria.

Other Name: Panobinostat

Study Arms

• Experimental: Treatment (STRATUM 1)
  Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
  Intervention: Drug: LBH589
• Experimental: Treatment (STRATUM 2)
  Patients with non-progressed DIPG will be enrolled. All patients will take the study drug panobinostat (LBH589).
  Intervention: Drug: LBH589

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: February 11, 2022): 53
• Original Estimated Enrollment (submitted: March 17, 2016): 20
• Estimated Study Completion Date: March 31, 2024
• Actual Primary Completion Date: February 14, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

STRATUM 1 - INCLUSION CRITERIA

• DIAGNOSIS - Patients with progressive DIPG, as defined by progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean, electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the bi-dimensional measurement, taking as a reference the smallest disease measurement recorded since diagnosis, OR the appearance of a new tumor lesion since diagnosis.

  • Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
  • Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma WHO II-IV.
• AGE - Patients must be ≥ 2 but < 22 years of age at the time of enrollment.

• BSA

  • Patients must have a BSA ≥ 0.80 m2 for dose 5mg/m2.
  • Patients must have a BSA ≥ 0.65 m2 for doses of 10mg/m2 - 22 mg/m2.
  • Patients must have a BSA ≥ 0.50 m2 for doses of 28 mg/m2 - 36 mg/m2.
• ABILITY TO SWALLOW - Patient must be able to swallow capsules whole.
• PERFORMANCE STATUS - Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within 7 days of enrollment must be ≥ 50%. Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
• PRIOR THERAPY - Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment. Patients must have recovered from the acute treatment-related toxicities (defined as < grade 1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
• MYELOSUPPRESSIVE CHEMOTHERAPY - Patients must have received their last dose of known myelosuppressive anticancer therapy or immunotherapy at least 21 days prior to enrollment (42 days if prior nitrosourea).

• INVESTIGATIONAL/ BIOLOGIC AGENT:

  • Biologic or investigational agent (anti-neoplastic): Patient must have recovered from any acute toxicity potentially related to the agent and received their last dose of the investigational or biologic agent ≥ 7 days prior to study enrollment. (For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur, and discussed with the principal investigator.)
  • Monoclonal antibody treatment and agents with known prolonged half-lives: At least three half-lives must have elapsed prior to enrollment. (Note: A list of the half-lives of commonly used monoclonal antibodies is available on the PBTC webpage under Generic Forms and Templates.)

• RADIATION THERAPY - Patients must have had their last fraction of:

  • Craniospinal irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
  • Focal irradiation to the primary site > 42 days prior to enrollment
  • Local palliative irradiation other than previously irradiated primary site (small port) ≥ 14 days

• ORGAN FUNCTION - Patients must have adequate organ and marrow function as defined below:

  • Absolute neutrophil count ≥ 1,000/mm3
  • Platelets ≥ 100,000/ mm3 (unsupported, defined as no platelet transfusion within 7 days, and recovery from post-transfusion nadir)
  • Hemoglobin ≥ 8 g/dl (may receive transfusions)
  • Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
  • ALT(SGPT) < 3 x institutional upper limit of normal
  • Albumin ≥ 3 g/dl
  • Potassium ≥ LLN
  • Serum total calcium (correct for serum albumin) or ionized calcium ≥ LLN

  • Serum creatinine based on age/gender as noted below. Patients that do not meet the criteria below but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 ml/min/1.73 m2 are eligible. Maximum Serum Creatinine for age/gender:

    • Age 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
    • Age 6 to < 10 years: 1 mg/dL (male); 1 mg/dL (female)
    • Age 10 to < 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female)
    • Age 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
    • Age ≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)

  • Cardiac Function:

    • Left ventricular ejection fraction ≥ 50 by gated radionuclide study OR shortening fraction of ≥ 27% by echocardiogram
    • Patient has no ventricular arrhythmias except for benign premature ventricular contractions.
    • Patient has a QTc interval < 450 ms.
• GROWTH FACTORS - Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patients received PEG formulations.
• FRUIT - Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study.
• PREGNANCY STATUS - Female patients of childbearing potential must have a negative serum or urine pregnancy test.
• PREGNANCY PREVENTION - Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after the last dose of panobinostat.
• INFORMED CONSENT - The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.

STRATUM 1 - EXCLUSION CRITERIA

• PRIOR THERAPY

  • Patients who have had > 60 Gy total radiation to the pons (e.g. patients who have received re-irradiation).
  • Patients have had prior HDAC, DAC, HSP90 inhibitors for the treatment of their DIPG.
  • Patients have had valproic acid within 28 days prior to enrollment.
  • Patients have had prior bone marrow transplant.
• NEUROLOGICAL STATUS - Patients have significant acute deterioration in neurologic status in 72 hours prior to enrollment, in the opinion of the treating physician.

• GASTROINTESTINAL

  • Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease.
  • Patients have diarrhea > CTCAE grade 2.
• SYSTEMIC ILLNESS - Patients have any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the ability of the patient to tolerate protocol therapy or put them at additional risk for toxicity or would interfere with the study procedures or results.
• OTHER MALIGNANCY - Patients have a history of any other malignancy.
• TRANSFUSIONS - Patients are known to be refractory to red blood cell or platelet transfusions.

• CONCURRENT THERAPY

  • Patients who are receiving any other anticancer or investigational drug therapy
  • Patients who are required to receive any medication which can prolong the QTc interval. Please see Protocol Appendix B: Medications Which May Cause QTc Prolongation.
• BREASTFEEDING - Female patient IS breastfeeding.
• INABILITY TO PARTICIPATE - Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions

STRATUM 2 - INCLUSION CRITERIA

• DIAGNOSIS - Patients with DIPG who have not yet progressed by clinical or radiographic criteria.

  • Please note: patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
  • Patients with pontine lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of malignant glioma WHO II-IV.
• AGE - Patients must be ≥ 2 but < 22 years of age at the time of enrollment.
• BSA Patients must have a BSA ≥ 0.80 m2 for dose 5mg/m2. Patients must have a BSA ≥ 0.65 m2 for doses of 10mg/m2 - 22 mg/m2. Patients must have a BSA ≥ 0.50 m2 for doses of 28 mg/m2 - 36 mg/m2.
• ABILITY TO SWALLOW - Patient must be able to swallow capsules whole.
• PERFORMANCE STATUS - Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score (LPS for ≤ 16 years of age) assessed within 7 days of enrollment must be ≥ 50%. Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

• PRIOR THERAPY - Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment. Patients must not have received any other prior therapy for treatment of their CNS malignancy besides standard radiation therapy.

  o Patients must have recovered from the acute treatment-related toxicities (defined as < grade 1) of radiotherapy prior to entering this study.

• RADIATION THERAPY - Patients must have had their last fraction of focal irradiation to the primary site > 14 days prior to enrollment. Patients must not have received local palliative irradiation or craniospinal irradiation.

• ORGAN FUNCTION - Patients must have adequate organ and marrow function as defined below:

  • Absolute neutrophil count ≥ 1,000/mm3
  • Platelets ≥ 100,000/ mm3 (unsupported, defined as no platelet transfusion within 7 days, and recovery from post-transfusion nadir)
  • Hemoglobin ≥ 8 g/dl (may receive transfusions)
  • Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
  • ALT(SGPT) < 3 x institutional upper limit of normal
  • Albumin ≥ 3 g/dl
  • Potassium ≥ LLN
  • Serum total calcium (correct for serum albumin) or ionized calcium ≥ LLN

  • Serum creatinine based on age/gender as noted below. Patients that do not meet the criteria in Table 9 but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 ml/min/1.73 m2 are eligible.

    • Age 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
    • Age 6 to < 10 years: 1 mg/dL (male); 1 mg/dL (female)
    • Age 10 to < 13 years: 1.2 mg/dL (male); 1.2 mg/dL (female)
    • Age 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
    • Age ≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)

• CARDIAC FUNCTION:

  • Left ventricular ejection fraction ≥ 50 by gated radionuclide study OR shortening fraction of ≥ 27% by echocardiogram
  • Patient has no ventricular arrhythmias except for benign premature ventricular contractions.
  • Patient has a QTc interval < 450 ms.
• GROWTH FACTORS - Patients must be off all colony-forming growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin). 14 days must have elapsed if patients received PEG formulations.
• FRUIT - Patients must agree to avoid grapefruit or grapefruit juice and Seville (sour) oranges during the entire study.
• PREGNANCY STATUS - Female patients of childbearing potential must have a negative serum or urine pregnancy test.
• PREGNANCY STATUS - Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after the last dose of panobinostat.
• INFORMED CONSENT - The patient or parent/guardian is able to understand the consent and is willing to sign a written informed consent document according to institutional guidelines.

STRATUM 2 - EXCLUSION CRITERIA

• PRIOR THERAPY - Patients who have had > 60 Gy total radiation to the pons (e.g. patients who have received re-irradiation)
• NEUROLOGICAL STATUS - Patients have significant acute deterioration in neurologic status in 72 hours prior to enrollment, in the opinion of the treating physician.

• GASTROINTESTINAL

  • Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease.
  • Patients have diarrhea > CTCAE grade 2.
• SYSTEMIC ILLNESS - Patients have any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator would compromise the ability of the patient to tolerate protocol therapy or put them at additional risk for toxicity or would interfere with the study procedures or results.
• OTHER MALIGNANCY - Patients have a history of any other malignancy.
• TRANSFUSIONS - Patients are known to be refractory to red blood cell or platelet transfusions.

• CONCURRENT THERAPY

  • Patients who are receiving any other anticancer or investigational drug therapy
  • Patients who are required to receive any medication which can prolong the QTc interval. Please see Appendix B: Medications Which May Cause QTc Prolongation.
• BREASTFEEDING - Female patient is breastfeeding.
• INABILITY TO PARTICIPATE - Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years to 21 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02717455
• Other Study ID Numbers: PBTC-047
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Pediatric Brain Tumor Consortium
• Original Responsible Party: Same as current
• Current Study Sponsor: Pediatric Brain Tumor Consortium
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Michelle Monje, MD, Phd; Stanford University

• PRS Account: Pediatric Brain Tumor Consortium
• Verification Date: April 2022